Executive Management Team

Joerg Ahlgrimm

Chief Executive Officer

Joerg Ahlgrimm is the Chief Executive Officer of SK Pharmteco. He is an Operations and Supply Chain Management Executive who has served in multi-billion dollar companies operating in biotech, vaccines, pharmaceutical and medical device markets.

Joerg is the former Head of Global Operations Pharma and Biotech at Lonza AG where he was responsible for 37 sites on four continents. Prior to Lonza, he headed the Manufacturing network of Baxter Bioscience/Baxalta with 17 plants, a significant CMO network and the largest plasma collection division of the company. Joerg's prior roles also included responsibility for Supply Chain for Baxter Bioscience. Joerg has a passion for saving lives which is his main motivator to work in healthcare. He enjoys leading teams to achieve unprecedented performance levels and to create a work environment where people bring their best. In 2014 he was awarded “Emerging Pharma Leader.”

David Lowndes

Chief Operating Officer

David joined SK pharmteco as COO in January 2023 bringing over 38 years of experience in the Pharmaceutical and Biotechnology Industry. He has experience living and working in the UK, Ireland, the Middle East, Eastern Europe and North Africa, Japan and the US. Most recently David was an Independent Member of the Board of SK pharmteco and of Yposkesi, prior to that he held successive Senior Vice President roles at Shire Pharmaceuticals with Global responsibility for Supply Chain and for Manufacturing. Shire operated an almost exclusively outsources supply network and David brings a strong Client perspective to his new role. While at Shire, David had leading roles in a number of acquisition due diligences, and in the subsequent integration of acquired businesses.

Prior to joining Shire, David has worked for Genzyme, Eli Lilly, Rhone Poulenc Rorer, SPIMACO and Ciba-Geigy.

David has a degree in Pharmacy from the Welsh School of Pharmacy, University of Wales Institute of Science and Technology (now Cardiff University).

Seung Chul Son

VP, Strategy

Seung Chul Son is Vice President of Strategy at SK pharmteco. He is a Chartered Financial Analyst and a US Certified Public Accountant.

Seung Chul joined SK in 2007, initially with SK Networks, since then he has held a number of strategy and M&A global roles in Korea, Colombia and the United States.

He was a key member of SK SUPEX Council Strategy team and SK Inc.’s Investment Center team prior to joining SK pharmteco, SK Inc’s pharma CDMO division in 2018.

Alain Lamproye

Chief Executive Officer, Yposkesi

Alain Lamproye joined as Chief Executive Officer of Yposkesi in January 2017. Alain previously served as President of the BioPharma Business Unit of Novasep, as well as CEO of its subsidiary dedicated to gene therapy (Henogen, Belgium). Alain has held various managerial positions in pharmaceutical operations at Merck Serono, including serving as Site Director at Billerica (USA). He also worked as GMP Production Director at Eurogentec (Belgium) for 14 years.

Alain holds a Master of Science in Biology from the University of Liège (Belgium).

Jeffrey Butler, PhD

President, AMPAC Fine Chemicals

As President of AMPAC Fine Chemicals (AFC), Jeff is responsible for operations across all AFC facilities. Jeff joined AFC as a Process Scientist where he held technical and business leadership roles of increasing responsibility, including Vice President of Project Management.
Jeff holds a PhD in Chemistry from the University of California, Davis. He conducted his Postdoctoral research in Chemistry at the University of Texas, Austin.

Keun-Joo Hwang

Chief Executive Officer, SK biotek Korea

Keun-Joo serves as the Chief Executive Officer of SK biotek. In 1995, Keun-Joo joined SK Group as a Planning Manager for SK Telecom's Business Strategy team. In 2017, he moved to the Investment Center of SK Holdings leading execution of M&A’s into new business areas, such as the pharmaceutical industry.

Keun-Joo has led many projects including the acquisition of Swords Campus in Dublin, Ireland, the acquisition of AMPAC Fine Chemicals and the establishment of SK pharmteco in the U.S. He holds a Master's and Bachelor's degree in Economics from Seoul National University.

William DuBay, PhD

VP Global Research and Development

Bill is Vice President of Global Research and Development for SK pharmteco. He is responsible for developing SK pharmteco's pipeline across six manufacturing sites. Bill has over 25 years of experience in Process Chemistry, Project Management and Business Development.

Prior to SK pharmteco, Bill held various positions at Wyckoff, Catalytica, DSM and AMPAC Fine Chemicals. Bill has a PhD in Organic Chemistry from the University of South Carolina and undertook his Postdoctoral studies at Indiana University.

Hyunjoon Kim

VP Global Operational Excellence

Hyunjoon is Vice President of Global Operational Excellence and is responsible for optimizing operations across manufacturing sites in Korea, Ireland and US. Hyunjoon has over 20 years of API experience in Operations and Engineering.

Hyunjoon joined SK in 1997. Over the course of his career he led various projects including process scale-up, optimization of commercial manufacturing and plant design & construction. Hyunjoon holds a Master’s degree in Chemical Engineering from the Korea University in Seoul, Korea.

Jeff Robinson

VP, Global Regulatory Affairs/IT

Jeff oversees cGMP compliance and agency Regulatory Affairs for SK pharmteco. Jeff has over 40 years of experience interfacing with the FDA and multiple foreign regulatory agencies. Jeff also oversees Information Technology and Continuous Improvement activities across SK pharmteco operations.

Jeff held similar positions at Schering-Plough, Aerojet Fine Chemicals and AMPAC Fine Chemicals. He holds a Bachelor’s degree in Chemical Engineering from the University of Washington and an MBA from California State University, Sacramento.

Tim Buckley

VP, Global Quality

Tim is an experienced Quality professional having spent over 30 years in the pharmaceutical industry supporting sterile semi solids, oral solid dose drug product and active pharmaceutical ingredient manufacture.

Tim has held multiple leadership roles within Quality functions at both site and corporate levels, including the position of Qualified Person, demonstrating effective communication skills combined with detailed product quality and compliance knowledge. Tim joined SK biotek in 2018 as the Global Head of Quality with overall responsibility for the development and consistent implementation of SKBT Quality Management System across its network of sites. Tim is now Global Head of Quality for SK pharmteco (SK biotek’s parent).

In addition to Tim’s primary degree is in Applied Chemistry & Physics (Trinity College Dublin), Tim also has an MSc in Analytical Chemistry (Dublin City University) and a Post Grad. Dip. in Pharmaceutical Manufacturing (Trinity College Dublin).

Don Whiteaker

VP, Global Supply Chain

Don is the Vice President of Global Supply Chain at SK pharmteco. Don has many years of experience serving in Operations leadership roles for drug product and drug substance manufacturing at Abbott Laboratories, Baxter International, Boehringer Ingelheim and AMPAC Fine Chemicals over the span of his career.

Don serves on charitable boards such as the American Red Cross and the National Hemophilia Foundation. He holds a Bachelor's degree from University of Cincinnati and an MBA from Case Western University.

Larry Zeagler

VP Global Legal/Contracts

Larry is responsible for SK pharmteco’s Legal Center of Excellence and managing the Pharma Products business enterprise. Larry has over 40 years of experience in the fine chemicals industry, 17 of which have been with AMPAC Fine Chemicals and SK pharmteco.

Larry previously held positions in R&D, Manufacturing and Business Development with Hoechst Celanese Corporation and Honeywell Pharmaceutical Fine Chemicals. Larry holds a Master's degree in Chemical Engineering.

Jaeyon Yoon, PhD

VP, Business Development (US & Asia)

Jaeyon has over 30 years of experience in the pharmaceutical industry. In 1990 Jaeyon joined as a starting member for SK biotek. He has worked in R&D, Business Development, Marketing and M&A activities.

Jaeyon holds a degree in Chemistry from Yonsei University in Seoul, Korea. He received his PhD from Case Western Reserve University. He undertook a Postdoctoral research position in Organometallic and Organic Chemistry at the University of North Carolina, Chapel Hill.

Steve Barr, PhD

VP, Business Development (Europe)

Steve has 30 years’ experience in the Pharma and CDMO space. Following completion of a PhD in Organic chemistry at the University of Glasgow, Steve spent his early career working with large pharma in a range of technical and operational roles. He then moved into strategic sourcing and procurement before moving into Business development. Over the last 19 years Steve has worked with a variety of leading CDMO’s, taking progressive senior commercial responsibilities. He joined SK in June 2018.

Christophe Cambouris

Chief Commercial Officer, Yposkesi

Christophe Cambouris joined Yposkesi, an SK pharmteco Company, as Chief Commercial Officer in July 2022. With over 20 years of business experience in the cell and gene therapy field, Christophe has held several business development and marketing positions. Including 14 years at Miltenyi Biotec where he was Sales and Marketing Director then European Director for Strategic Accounts.

Christophe holds an Immunology master’s degree from the Ecole Pratique des Hautes Etudes in Paris.

Contact Us

For Business Development & Marketing Enquires contact